Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 4069

Provisional Schedule

Expected publication 12 June 2024

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Pharmaand
Others Department of Health and Social Care
  NHS England
Patient carer groups Target Ovarian Cancer
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies GlaxoSmithKline
General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium (part of Healthcare Improvement Scotland)
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
02 November 2023 Invitation to participate
01 July 2023 - 22 July 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
06 April 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
06 April 2022 In progress. Review of TA611

For further information on our processes and methods, please see our CHTE processes and methods manual